Exhibition Preview | Nanodigmbio invites you to the Annual Meeting of the European Association for Cancer Research (EACR) 2024 in the Netherlands

01 Introduction to the Conference

The Annual Meeting of the European Association for Cancer Research 2024 (EACR 2024) will be held in Rotterdam, the Netherlands, on June 10-13, 2024. The EACR is committed to advancing cancer research, and the Congress covers all areas of cancer research, including basic, preclinical, translational and clinical. The conference will explore a range of the latest research topics, present the latest research results and provide opportunities for interaction, discussion and new partnerships.

EACR 2024 is expected to bring together more than 2,100 attendees, including: senior scientists, principal researchers, the academic research community, industry researchers, clinicians, and more. During the Congress, 16 symposia will be held on topics including: cancer genomics, bioinformatics and computational biology, Biomarkers in tissues and blood, epigenetics, liquid biopsy, precision cancer medicine in the post-genomic era, mechanisms of tumor metastasis, prevention and early detection, spatial analysis of tumors/spatial transcriptomics, targeting cancer mitochondria, etc. The EACR combines high quality presentations that showcase cutting-edge research while providing an excellent opportunity for excellent networking with professionals from diverse backgrounds.

02 Nanodigmbio TIME

Booth information

[Conference Time] June 10-13, 2024

[Venue] Rotterdam-AHOy Exhibition Center, the Netherlands

[Nanodigmbio Booth] NO. 45

Welcome to visit the Nanodigmbio booth!

03 Product Recommendation

μCaler Total Solution for Methylation

μCaler Targeted Methylation Sequencing Comprehensive Solution, featuring an exclusive patented μCaler hybridization capture system, enabling the completions of the entire process within same day with simple and convenient operations. This solution captures the converted methylation libraries using a patented probe design scheme that covers targets in all methylation states. Furthermore, with a hybridization capture system optimized for methylation is not only suitable for targeted enrichment with mini-Panels but also applicable for capturing special regions like AT-rich sequences. The μCaler EMS Panel v1.0 (Early Methylation for Screening, abbreviated as "EMS") provides a comprehensive and optimized methylation technology solution for the early screening and detection of cancer.

μCaler EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It passes nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma cancer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinog enesis and tumor suppression, with over 2,000 CpG sites. The probe design covers approximately 20 Kb of the human genome, providing comprehensive and accurate support for methylation early screening.

One-Stop Service for Customized Probes

NAD Probe is a one-stop service created by Nanodigmbio, covering the entire process from probe design, probe production, quality inspection, optimization, and result delivery. Through strict quality control (QC) and optimized NGS QC services, we can provide our customers with high-quality customized hybridization capture solutions, covering the application types in addition to conventional mutation detection, which include methylation capture, RNA capture, and virus capture.